On June 15, Sino Biopharmaceutical rose 3.19% in regular trading, trading at HK$4.85 per share, with turnover of approximately HK$120 million.

On the news front, the company announced that its board of directors approved a share purchase plan on June 12, authorizing up to HK$2 billion in total consideration over the next 12 months for open-market share repurchases and acquisitions of shares needed for its restricted share award scheme. Since the beginning of the year, the company has already accumulated purchases of approximately 60.35 million shares at a total cost of about HK$338 million. The substantial buyback plan signals management's strong confidence in the company's intrinsic value and is expected to provide sustained price support.

Within the Pharmaceuticals sector, sentiment was broadly positive, with peer CSPC Pharmaceutical rising 3.18%, Simcere Pharmaceutical up 0.79%, and Luye Pharma up 0.53%, reflecting a generally constructive tone across the industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)